- Companies
- GridAI Technologies
GridAI Technologies Valuation Multiples
GridAI Technologies is valued at $35M as of November 2026. In the last fiscal year, GridAI Technologies revenue was $36K and GridAI Technologies EBITDA was ($6M).
GridAI Technologies Overview
About GridAI Technologies
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company’s programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Founded
2014
HQ
Employees
2
Website
Sectors
Financials (Last FY)
EV
$45M
Valuation Multiples
Start free trialGridAI Technologies Financials
GridAI Technologies reported last fiscal year revenue of $36K and negative EBITDA of ($6M).
In the same fiscal year, GridAI Technologies generated ($657K) in gross profit, ($6M) in EBITDA losses, and had net loss of ($6M).
GridAI Technologies P&L
In the most recent fiscal year, GridAI Technologies reported revenue of $36K and EBITDA of ($6M).
GridAI Technologies is unprofitable as of last fiscal year, with gross margin of (1814%), EBITDA margin of (15377%), and net margin of (17634%).
Financial data powered by Morningstar, Inc.
GridAI Technologies Stock Performance
GridAI Technologies has current market cap of $35M, and enterprise value of $45M.
Market Cap Evolution
GridAI Technologies' stock price is $3.44.
GridAI Technologies share price decreased by 30.6% in the last 30 days.
GridAI Technologies has an EPS (earnings per share) of $-0.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45M | $35M | 5.2% | -30.6% | -9.7% | - | $-0.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGridAI Technologies Valuation Multiples
GridAI Technologies trades at 1228.3x EV/Revenue multiple, and (8.0x) EV/EBITDA.
GridAI Technologies Financial Valuation Multiples
As of November 19, 2026, GridAI Technologies has market cap of $35M and EV of $45M.
GridAI Technologies has a P/E ratio of (5.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GridAI Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GridAI Technologies Margins & Growth Rates
In the most recent fiscal year, GridAI Technologies reported gross margin of (1814%), EBITDA margin of (15377%), and net margin of (17634%).
GridAI Technologies Margins
GridAI Technologies Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GridAI Technologies Operational KPIs
GridAI Technologies' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
GridAI Technologies Competitors
GridAI Technologies competitors include Caribou Biosciences, Rekah Pharmaceutical, Cantargia, Serina Therapeutics, Grace Therapeutics, Neurizon Therapeutics, LeonaBio, Instil Bio, Corline Biomedical and Alterity Therapeutics.
Most GridAI Technologies public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $11M | ($145M) | - | - | - | - | |||
| $93M | $8M | 0.8x | - | 9.0x | - | |||
| $31M | $15M | 0.4x | 3.3x | 0.9x | (1.3x) | |||
| - | ($19M) | - | 282.3x | (1.0x) | - | |||
| - | ($10M) | - | - | (1.5x) | (1.4x) | |||
| $2M | ($4M) | 13.6x | 7.0x | (6.5x) | (2.9x) | |||
| - | ($105M) | - | - | (0.0x) | - | |||
| - | ($70M) | - | - | (0.9x) | - | |||
This data is available for Pro users. Sign up to see all GridAI Technologies competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by GridAI Technologies
GridAI Technologies has acquired 3 companies to date.
Last acquisition by GridAI Technologies was on November 13th 2026. GridAI Technologies acquired Pronghorn Resources for undisclosed valuation.
Latest Acquisitions by GridAI Technologies
| Description | Pronghorn Resources is a natural gas production and energy infrastructure business operating in Wyoming's Powder River Basin. It holds mineral and leasehold interests, producing gas wells, owned gathering pipelines and compression facilities connected to regional transportation systems, and it also produces fresh water. The company sells natural gas and related services, and its sites include large tracts suited to data center and power development. It is organised as a Wyoming limited liability company with its base in Sheridan, Wyoming. GridAI Technologies agreed in November 2026 to acquire it through a share exchange, with the aim of supplying dedicated power to AI data centers. | Grid AI develops software that orchestrates power for AI data center campuses. Its platform coordinates grid supply, on-site generation, battery storage, backup and flexible load across large campuses, distributed power systems and homes. | First Wave Bio is a clinical-stage biopharma company developing oral and rectal therapies for inflammatory bowel diseases like ulcerative colitis. Its lead candidate, FW-UP, a gut-selective JAK inhibitor, advances in Phase 2 trials following positive Phase 1b results showing safety and efficacy. Headquartered in Israel with U.S. operations, the pipeline includes distally acting compounds to reduce systemic exposure. Listed on NASDAQ as FWBI since 2019, it collaborates with CROs for global trials targeting unmet needs in IBD treatment. |
| HQ Country | |||
| HQ City | Sheridan, WY | Edinburgh | Miami, FL |
| Deal Date | 13 Nov 2026 | 1 Oct 2025 | 16 Sep 2021 |
| Valuation | undisclosed | undisclosed | $229M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all GridAI Technologies acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GridAI Technologies
| When was GridAI Technologies founded? | GridAI Technologies was founded in 2014. |
| Where is GridAI Technologies headquartered? | GridAI Technologies is headquartered in United States. |
| How many employees does GridAI Technologies have? | As of today, GridAI Technologies has over 2 employees. |
| Is GridAI Technologies publicly listed? | Yes, GridAI Technologies is a public company listed on Nasdaq. |
| What is the stock symbol of GridAI Technologies? | GridAI Technologies trades under GRDX ticker. |
| When did GridAI Technologies go public? | GridAI Technologies went public in 2016. |
| Who are competitors of GridAI Technologies? | GridAI Technologies main competitors include Caribou Biosciences, Rekah Pharmaceutical, Cantargia, Serina Therapeutics, Grace Therapeutics, Neurizon Therapeutics, LeonaBio, Instil Bio, Corline Biomedical, Alterity Therapeutics. |
| What is the current market cap of GridAI Technologies? | GridAI Technologies' current market cap is $35M. |
| What is the current revenue of GridAI Technologies? | GridAI Technologies' last fiscal year revenue is $36K. |
| What is the current EV/Revenue multiple of GridAI Technologies? | Current revenue multiple of GridAI Technologies is 1228.3x. |
| Is GridAI Technologies profitable? | No, GridAI Technologies is not profitable. |
| How many companies GridAI Technologies has acquired to date? | As of November 2026, GridAI Technologies has acquired 3 companies. |
| What was the largest acquisition by GridAI Technologies? | $229M acquisition of First Wave Bio on 16th September 2021 was the largest M&A GridAI Technologies has done to date. |
| What companies GridAI Technologies acquired? | GridAI Technologies acquired First Wave Bio, Pronghorn Resources, and GRID AI. |
| In how many companies GridAI Technologies has invested to date? | GridAI Technologies hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to GridAI Technologies
Lists including GridAI Technologies
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




